Monocyte chemoattractant protein 1 (MCP-1) (MCP-1)

Monocyte chemoattractant protein 1 (MCP-1), also known as C-C motif chemokine ligand 2 (CCL2), is a member of the CC chemokine family that plays a pivotal role in the selective recruitment of monocytes, memory T lymphocytes, and dendritic cells to sites of inflammation (UniProt P13500). It is produced by a variety of cell types, including monocytes, macrophages, fibroblasts, and endothelial cells, often in response to inflammatory stimuli such as lipopolysaccharide (LPS) or pro-inflammatory cytokines (PubMed: 19452352). MCP-1 functions primarily by binding to the G protein-coupled receptor CCR2, triggering signal transduction pathways that lead to chemotaxis and cellular activation (PubMed: 21970434). In clinical contexts, elevated levels of MCP-1 are associated with numerous inflammatory conditions, including atherosclerosis, rheumatoid arthritis, and diabetic nephropathy, where it drives chronic tissue infiltration by immune cells (PubMed: 15123773). Furthermore, MCP-1 is implicated in cancer progression, as it can recruit tumor-associated macrophages that promote angiogenesis and immunosuppression (PubMed: 24561990). Therapeutic targeting of MCP-1 involves the use of neutralizing antibodies, such as carlumab, or small molecule inhibitors like bindarit that suppress its synthesis (ClinicalTrials.gov: NCT00992186). While targeting this pathway holds promise for treating chronic inflammation, challenges include the potential for redundant chemokine signaling and the need to maintain adequate host defense mechanisms (PubMed: 22439098). Monitoring MCP-1 levels in serum or tissue is often used as a biomarker for disease activity and therapeutic response in clinical trials.

Other names

CCL2C-C motif chemokine ligand 2Small inducible cytokine A2Monocyte chemotactic and activating factorMCAFHC11

Neutralization of the chemokine ligand to prevent binding to the CCR2 receptor or inhibition of the transcriptional synthesis of the chemokine.